ClinicalTrials.gg
Not yet recruitingNCT06866236NAD agentUpdated Sep 8, 2025

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

A Phase 2/3 interventional study of QRX-3 in Chronic Kidney Diseases, Acute Kidney Injury and Kidney Failure, sponsored by Ebima Clifford Okundaye. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Ebima Clifford Okundaye · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Planned enrollment
24th of 819
3,000 · median 72
Started
2025
with 56 others
Phase 2/3
13 of 988
1 open now
Primary completion
2026-10
later than 39 of 216 live
Registered
897th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 24th largest by planned enrollment of the 819 interventional ones that give a count, is one of 57 that started in 2025, is one of 13 in phase 2/3, reaches primary completion later than 39 of the 216 other live ones, and was the 897th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Read the detailed description

Chronic kidney disease has been linked to impaired activity of mitochondrial dysfunction along with oxidative intracellular mechanisms that result in the cascade of progressive damage within renal tubular cells. Several treatment options for mitochondrial dysfunction have been suggested to target the loss of nephrons via renal fibrosis and tubular senescence of the kidney cells by enhancing the mitochondrial activity of these cells via the NAD/NAD+ redox pathway as well as reduce the presence of fibrogenic intracellular inflammatory markers .

QRX-3 is a formulated novel drug designed to supply and optimize NAD+ mitochondrial availability and prevent this nephron loss .

In this study the investigators will evaluate the effect of intervention with this novel drug therapy on chronic kidney disease CKD population with slowly declining renal function.

03

Conditions studied

  • Chronic Kidney Diseases
  • Acute Kidney Injury
  • Kidney Failure

Keywords

  • CKD, CKD treatment , renal function
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria

    • Patient with Chronic kidney disease
    • Estimated Glomerular function by of less than 60mls/min
    • Patients with declining renal function ( as measured by eGFR by MDRD )
    • Rate of decline of eGFR over the last one year of less than 20%
    • Negative Serology markers for CKD etiology
    • Provider perceived adherence to study follow up

Exclusion Criteria:

Rapid rate of decline in kidney function of > 20 % over last one year

  • Symptomatic renal failure
  • Presence of any suspected Acute renal failure superimposed
  • Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
  • No known reversible cause of renal decline
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
3,000 participants (estimated)

Study arms

  • Active comparator
    intervention

    QRX-3 - two capsules orally twice daily

    Drug: QRX-3

  • Placebo comparator
    placebo

    placebo pill - one capsule orally twice daily

    Drug: QRX-3

Interventions

  • DrugQRX-3

    capsule

06

What researchers measure

Primary outcomes

  1. change in Glomerular filtration rate

    change percentage in kidney function level measured with cystatin creatinine glomerular filtration rate

    Time frame: 1 year

Secondary outcomes

  1. change in Proteinuria

    change in random urine protein/creatinine ratio

    Time frame: 1 year

  2. change in rate of Glomerular filtration rate decline

    comparism of slopes of decline in cystatin creatinine glomerular filtrate rate

    Time frame: 1 year

07

Study locations

1 site
  • Neukidney Inc
    Pasedena, Texas 77504, United States
08

References and documents

Individual participant data

Plan to share: Yes — de-identified information of each participants trial characteristics will be available for sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Oct 2026, 12 months later.

Of 11 phase 2/3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 56. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 10, 2025
StartEst.
Oct 2025
Primary completionEst.
Oct 2026
CompletionEst.
Jul 2027
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06866236
Lead sponsor
Ebima Clifford Okundaye
Responsible party
Ebima Clifford Okundaye (President, Neukidney Inc.) — Sponsor-investigator
First posted
Mar 10, 2025
Start date
Oct 2025 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Sep 8, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion